Report Overview

The Global Antithrombin Market was pegged at US$ 550 million in 2021 and is expected to witness a CAGR of 3.90% during the forecast period.

Market Fundamentals

Antithrombin (AT) is a naturally occurring small glycoprotein that maintains the balance in the coagulation system. Antithrombin inhibits thrombin and factor XA, the key proteases for blood coagulation. Antithrombin is recommended in the cases of thromboembolism. People with antithrombin deficiency are at a higher risk of getting blood clots during surgery and pregnancy. Antithrombin deficiency creates abnormal genes that leads to abnormal blood coagulation and can damage organs. Antithrombins such low molecular weight heparin, unfractionated heparin, and bivalirudin are suggested for those with unstable angina and myocardial infractions.

[45635435345]

Market Dynamics

The global antithrombin market is mainly driven by factors such as, increased risk of health conditions like sepsis, intravascular coagulations, and myocardial infractions. In addition, Increasing incidences of coagulation disorders, increased rates of kidney and heart failure (used extensively in dialysis and open-heart surgeries) are the key drivers of the global antithrombin market. Rising diagnostic tests that uses antithrombins is also triggering the market growth. However, the global antithrombin market is constrained by high cost of antithrombin medications. 

Market Ecosystem

The global antithrombin market has been analyzed from four perspectives: application, source, dosage and region. 

Global Antithrombin Market by Applications

[342323]

According to applications, the global antithrombin market is categorized into therapeutics, research, and diagnostics. Among these, the therapeutics segment has accounted the highest share in the global antithrombin market. Patients who have a congenital antithrombin deficiency are advised to use antithrombins. Additionally, antithrombins are employed when severe bleeding occurs during surgical procedures. These are used after surgeries to reduce blood clots. People with thrombin deficiency are at a higher risk of getting deep vein thrombosis (DVT) and pulmonary embolism. In addition, mostly people aged around 40 are likely to develop thrombosis that pulls away from the veins in the legs or pelvic region, and travels to lungs through blood stream which results in pulmonary embolism. Antithrombins (antithrombin III) in hereditary thromboembolism acts as plasma protease inhibitor, that inactivates thrombin and other activated coagulation factors. 

Global Antithrombin Market by Source 

The global antithrombin market based on sources, is divided into three segments:  human, goat milk, and bovine. Among these, the goat milk source has dominated the global market. Factors contributing this growth are high yield, short gestation period, and short time required for maturation makes goats perfectly suited for biopharmaceutical industries to perform recombinant DNA technology. ATryn is an anticoagulant derived from genetically transmitted goat milk is used to prevent blood clots in patients with genetic deficiency. 

Global Antithrombin Market by Dosage Form

The global antithrombin market according to dosage form is segmented into liquid and lyophilized. between the two types, the lyophilized antithrombin segment has dominated the market. This dominance of the segment is supported by factors such as enhancing the product stability in dry state, also they are present in single use vials. Also, lyophilized antithrombin segment has a prolonged expiration date. 

Global Antithrombin Market by Region

The global Antithrombin market has been divided into four geographic segments: North America, Europe, Asia Pacific, and the rest of the world. The North America has accounted the highest stake in the global antithrombin market. The factors contributing to this growth are increased cases of cardiovascular related diseases. Antithrombins are strong inhibitors of blood coagulation, which is important drug in myocardial related diseases. Europe has dominated the market after North America. The Factors affecting this region is due to robust development of technologies, high awareness, and increasing drug approvals. The Asia Pacific is also expected to show a profitable growth in the forecast period due to increasing coagulation related disorders, patients undergoing cardiac surgery experiences vital changes in inflammatory systems. 

Strategic Development 

• In June 2021 The U.S. FDA (Food And Drug Administration) approved Pradaxa oral tablets manufactured by Boehringer Ingelheim KG. Pradaxa is the only FDA-authorized blood thinner for kids aged 3 months to 12 years that may be taken orally; all other approved blood thinners for kids must be administered intravenously.
• In December 2020, The U.S. FDA (Food And Drug Administration) has approved Xarelto in tablet formulations to treat thromboembolism. The drug is manufactured by Janssen pharma Inc. The drug is used to treat patients up to 18 years of age. 

Competitive Landscape

Some of the prominent market players operating in the global antithrombin market are 

• Gilead Sciences Inc.
• Strategic Developments
• Bristol-Myers Squibb Company
• Novartis International AG
• Merck & Co.
• Shire Plc.
• Kedrion S.p.A
• Scripps Laboratories Inc.
• Lee Biosolutions
• Grifols S.A.
• CSL Behring GmbH

Frequently Asked Questions About This Report